This pragmatic trial addresses the clinical gap through the generation of evidence on the comparative effectiveness between AKYNZEO® and Standard of Care (SoC, including EMEND®) in the real-life setting

Inclusion Criteria:

• Male or female, Age ≥ 18 years
• Have a histological or cytological confirmed solid tumor malignancy
• Patient scheduled to receive their first course of anthracycline cyclophosphamide (AC) based chemotherapy regimen or Moderately Emetogenic Chemotherapy for the treatment of solid malignant tumor
• Patient scheduled to receive CINV prevention with AKYNZEO® or Standard of Care according to the summary of product characteristics based on the judgement of their investigator's
• Naïve of CT
• ECOG performance up to 2
• Able to read, understand and follow the study procedures
• Patient with Health insurance

Exclusion Criteria:

• Pregnancy and breastfeeding women;
• Hypersensitivity to active substances, excipients or other ingredients of Akynzeo® or Emend®;
• Protected patients: majors under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision